Response Pharmaceuticals’ RDX-002 meets primary endpoint in Phase Ib trial
Response Pharmaceuticals announced that the Phase Ib clinical trial yielded positive results for RDX-002, a novel treatment aimed at preventing antipsychotic-induced weight gain (AIWG). RDX-002 is a first-in-class candidate treatment for the prevention of …